Yahoo! Finance Canada report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Why HLF Stock advanced +0.93% Today — RQD Quant Desk Flash
Herbalife Ltd. (HLF) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Herbalife Ltd. (NYSE: HLF) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $13.05 (+0.93% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, HLF ranks #140 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HLF compare to NUS and ZSTK in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), HLF carries a Roarable C (64/100 RQD), trailing P/E of 5.9x, gross margin of 77.9%, and ROIC of 34.4%. By comparison, NUS (Nu Skin Enterprises Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC 6.7%, cap $228.3M) and ZSTK (ZeroStack Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $63.9M). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while HLF leads on capital efficiency (34.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HLF?
▼
Per HLF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001180262), Herbalife Ltd. generated $5.04B in revenue (+0.9% YoY), $228.3M in net income, and $252.9M in free cash flow against $2.79B in total assets and $1.97B in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 5% FCF Margin ($252.9M FCF) & 77.9% Gross Margin
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
⚔️ Adversarial Opposing Case: Why the HLF Bull Thesis Could Fail
Even with a 64/100 (C) score, HLF faces multiple-compression risk if 5.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.72) or 200D SMA ($13.99) invalidates the momentum regime and cuts Target Base ($13.40) toward Bear Floor ($10.45).
Why HLF Stock advanced +0.93% Today — RQD Quant Desk Flash
Herbalife Ltd. (HLF) advanced +0.93% to $13.05, trading at 43% of its 52-week range ($7.56 – $20.4). Solid 78% profit margin (34% return on capital), mixed timing at 6x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 43% of its 52-week range ($7.56 – $20.4) with RSI-14 at 45.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8% around $13.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 77.9% gross margin and $252.9M annual free cash flow.
GuruFocus report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Health and wellness products company Herbalife (NYSE:HLF) will be announcing earnings results this Monday afternoon. Here’s what you need to know.
Prioritize oral and multi-pathway drugs, telehealth, public-payer access, direct-to-patient channels, and muscle-preserving nutrition as generics widen global reachDublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Weight Loss M
Scheduled RQD Strong Buys & Whale Accumulation Briefing (HLF Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
HLF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HLF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HLF. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HLF)
1. Head-to-Head Health Care Peer Comparison (HLF vs. NUS, ZSTK, ESYN, CAH)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Herbalife Ltd. (HLF) ranks #140 by composite RQD confidence (64/100, grade C) and #320 by equity capitalization ($1.36B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while HLF leads on capital efficiency and profitability with 34.4% ROIC and 77.9% gross margin. CAH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with HLF at 64/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HLF
ACTIVE
Herbalife Ltd. | C | 64/100 | 5.9x | 77.9% | 34.4% | +0.93% | $1.36B | Benchmark Subject |
| NUS Nu Skin Enterprises Inc. | D+ | 53/100 | — | 69.4% | 6.7% | -0.85% | $228.3M | /nus-vs-hlf → |
| ZSTK ZeroStack Corp. | E | 25/100 | — | 4.6% | -35.0% | -5.12% | $63.9M | /zstk-vs-hlf → |
| ESYN EnerSyn Global Inc. | D- | 40/100 | — | 53.0% | -35.0% | -4.37% | $54.4M | /esyn-vs-hlf → |
| CAH Cardinal Health Inc. | B | 73/100 | 37.2x | 3.7% | 29.7% | -0.24% | $58.14B | /cah-vs-hlf → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001180262In its most recent audited fiscal period (FY2025, filed 2025-12-31), Herbalife Ltd. (HLF) reported GAAP revenue of $5.04B (+0.9% vs. FY2024 revenue of $4.99B , and -0.5% cumulative change since FY2023) , GAAP net income of $228.3M, operating cash flow of $333.3M, and free cash flow of $252.9M (+54.8% YoY). On the balance sheet, HLF closed FY2025 with $2.79B in total assets against $1.97B in total debt (Altman Z-Score: 2.39, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $5.04B | $228.3M | $333.3M | $252.9M | $2.79B | $1.97B |
| FY2024 (FY) | 2024-12-31 | $4.99B | $254.3M | $285.4M | $163.4M | $2.73B | $1.98B |
| FY2023 (FY) | 2023-12-31 | $5.06B | $142.2M | $357.5M | $357.5M | — | — |
3. HLF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HLF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Herbalife Ltd. (NYSE: HLF) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $13.05 (+0.93% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, HLF ranks #140 in composite RQD confidence.
How does HLF compare to NUS and ZSTK in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), HLF carries a Roarable C (64/100 RQD), trailing P/E of 5.9x, gross margin of 77.9%, and ROIC of 34.4%. By comparison, NUS (Nu Skin Enterprises Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC 6.7%, cap $228.3M) and ZSTK (ZeroStack Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $63.9M). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while HLF leads on capital efficiency (34.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HLF?
Per HLF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001180262), Herbalife Ltd. generated $5.04B in revenue (+0.9% YoY), $228.3M in net income, and $252.9M in free cash flow against $2.79B in total assets and $1.97B in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HLF trading relative to its 50-day, 200-day, and 52-week technical levels?
HLF last traded at $13.05 (+0.93% on volume of 1,520,210 shares), positioning the stock +2.59% above its 50-day simple moving average ($12.72) and -6.72% below its 200-day simple moving average ($13.99). Across its 52-week range of $7.56 to $20.40, HLF sits at the 42.8% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($12.01 to $14.09).
HLF Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HLF stock moving today?
Why HLF Stock advanced +0.93% Today — RQD Quant Desk Flash. Solid 78% profit margin (34% return on capital), mixed timing at 6x P/E—hold if owned, no rush to chase.
HLF — Herbalife Ltd.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, HLF scores 64 out of 100, earning a letter grade of C and the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 18 of 20 (ROIC 34.4%; FCF yield 18.66%), the strongest contributor and the main source of the score; Whale 13F Flow at 8 of 20 (institutional accumulation and options positioning), a weak contributor; Insider Conviction at 17 of 20 (SEC Form 4 and Congressional PTR cluster flow), a strong contributor; Macro Regime Fit at 9 of 20 (beta 1.0; sector sensitivity), a middling contributor; and Forensic Balance Sheet at 12 of 20 (Altman Z 2.39; Piotroski F 6/9; Debt/Equity 0.5), a moderate contributor.
For a prospective investor evaluating the stock today, the pillar mix suggests the cash-generation case is the principal argument in favor, supported by insider-flow signals. The lower whale-flow and macro-fit scores indicate less institutional confirmation and a beta of 1.0 that tracks the broader market and sector. Valuation tradeoffs are visible in the market data: a trailing P/E of 5.9 and EV/EBITDA of 5.4 sit alongside an FCF yield of 18.66%, while the stock trades near the lower portion of its 52-week range. The balance sheet is rated as moderate rather than weak, but the Altman and Piotroski readings and reported debt of $1971.7M warrant attention in weighing downside scenarios. This is an analytical summary, not personalized advice.
Snapshot
Business
Herbalife Ltd. (HLF) is a NYSE-listed issuer in the Health Care sector and Other Pharmaceuticals industry, per the Profile. Per the Market Data, the company reports a gross margin of 77.9%, an operating margin of 9.5%, and a net margin of 4.5%. Not available in source data for product lines, customer segments, or specific revenue-generation mechanics.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $5037.5M | $481.0M | $228.3M | N/A | $252.9M | $353.1M | $1971.7M |
| FY 2024 | $4993.1M | $385.9M | $254.3M | N/A | $163.4M | $415.3M | $1976.6M |
| FY 2023 | $5062.4M | $356.4M | $142.2M | N/A | $357.5M | N/A | N/A |
Per the SEC financials, revenue was broadly flat across the three reported periods, while operating income rose from $356.4M (FY 2023) to $481.0M (FY 2025). Net income moved from $142.2M to $254.3M and then to $228.3M. Per the Roarable RQD rating, ROIC is 34.4%, and the forensic inputs are an Altman Z-Score of 2.39, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. Cash declined from $415.3M to $353.1M over the two most recent periods, while debt was broadly stable at $1976.6M and $1971.7M.
Recent Catalysts & News Wire Analysis
Per the recent news data, the feed contains six items dated within roughly the past 15 hours, tagged by impact label:
- Market Wire (YELLOW): Yahoo! Finance Canada and Yahoo Finance coverage of general market action and fair-value commentary.
- Catalyst (GREEN): GuruFocus reported a share move of 4.5% alongside a GF Score of 62; MarketBeat reported a 5% share move.
- Risk Watch (RED): Benzinga listed HLF among "Top 3 Risk Off Stocks" for Q4.
- Catalyst (GREEN): Simply Wall St coverage addressed investor reaction to slowing sales growth.
Per the Butterfly Supply-Chain Graph, no proprietary signals or butterfly links are recorded. The headlines are summary-level and do not include underlying figures beyond those noted.
Open Questions
- What drives the reported revenue plateau across FY 2023–FY 2025, and what is the company's stated growth trajectory?
- What explains the decline in cash from $415.3M to $353.1M despite positive reported FCF in FY 2025?
- What are the terms, maturities, and interest costs on the $1971.7M of reported debt?
- What is the underlying basis for the 4.5% and 5% share moves referenced in the news wire, and do they reflect company-specific events?
- Why is EPS reported as N/A for every period despite positive net income?
HLF Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Herbalife Ltd. (HLF) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Herbalife Ltd. (HLF) market action, institutional positioning, and fundamental catalysts.
HLF Bull vs. Bear Conversation Board — What's Your Call at $13.05?
🔥 Official Bull vs. Bear Debate: Is HLF (C • RQD 64/100) a Buy at $12.93?
Welcome to the HLF (Herbalife Ltd.) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Other Pharmaceuticals. Bulls point to capital efficiency (34.4% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on HLF — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on HLF, but look at what you are paying: 5.9x trailing P/E with 77.9% gross margins. Unless Herbalife Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
HLF cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on HLF, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $12.93 (52-wk range $7.56 - $20.40), any beat on forward guidance forces shorts and underweight funds to chase.